Study #2024-0553
A phase 1 study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BG-T187, an EGFR×MET trispecific antibody, alone and in combination with other therapeutic agents in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BG-T187
Description
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-541-1846
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.